CVSI CV Sciences Inc

CV Sciences, Inc. to Sponsor 26th Annual HIACON Conference in Charlotte, North Carolina on Nov. 1-4, 2019

CV Sciences, Inc. to Sponsor 26th Annual HIACON Conference in Charlotte, North Carolina on Nov. 1-4, 2019

SAN DIEGO, Oct. 24, 2019 (GLOBE NEWSWIRE) -- . (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, announced today its title sponsorship of the Hemp Industries Association® (HIA®) annual conference and tradeshow, HIACON. This year’s conference will be held November 1st through November 4th in Charlotte, North Carolina, and marks a significant milestone for HIACON as the longest-standing hemp conference in its 26th year.

“We are looking forward to joining HIACON as the title sponsor for our 4th consecutive year,” said Joseph Dowling, Chief Executive Officer of CV Sciences. “Since 2014, CV Sciences has been dedicated to investing in hemp research and development to further the industry and the conference is the ideal platform to discuss the trends and opportunities occurring in this rapidly growing market.”

HIACON will bring together exhibitors, speakers and educators who represent the HIA’s coalition partnerships in the farm business, sustainability, herbal and dietary supplements, as well as hemp companies, business services, and brands showcasing product innovation. Attendees are invited to visit the CV Sciences team at Booth 405. Visitors can learn more about CV Sciences and its industry-dominating brand from experienced staff, who will be available to provide information to retailers and consumers interested in learning more about PlusCBD™ Oil hemp CBD products.

As title sponsor, CV Sciences will present during the Hemp Talk in a session titled “We Came, We Disrupted, What Now?” on Sunday, November 3rd, at 11:10 AM in the Providence Ballroom. CV Sciences’ Director of Hemp, Josh Hendrix, will share in-depth knowledge about hemp and perspectives as an established leader in the natural products industry.

CV Sciences and the HIA encourages both members and non-members to join the hemp industry’s top leaders and influencers at this year’s HIACON at The Westin Charlotte. The conference is opening the exhibit hall and Hemp Talks to the public, on Sunday, November 3, from 9:00 a.m. to 6:30 p.m. Only registered attendees will have full access and HIA members receive an exclusive discount on registration. HIACON will end on Monday, November 4, after a full day of keynote presentations and educational tracks, a half-day exhibition and the industries awards luncheon.

For more information about HIACON or to register, visit:

About CV Sciences, Inc. CV Sciences, Inc. (OTCQB:CVSI) operates two distinct business segments: a consumer product division focused on manufacturing, marketing and selling plant-based CBD products to a range of market sectors; and a drug development division focused on developing and commercializing CBD-based novel therapeutics utilizing CBD. The Company’s products are sold at more than 5,500 retail locations through the U.S. and it is the top-selling brand of hemp-derived CBD on the market, according to SPINS, the leading provider of syndicated data and insights for the natural, organic and specialty products industry.  CV Sciences’ state-of-the-art facility follows all guidelines for Good Manufacturing Practices (GMP) and the Company’s full spectrum hemp extracts are processed, produced, and tested throughout the manufacturing process to confirm the cannabinoid content meets strict company standards.  With a commitment to science, PlusCBD™ Oil’s benefits in healthy people are supported by human clinical research data, in addition to three published clinical case studies available on .  PlusCBD™ Oil was the first hemp CBD supplement brand to invest in the scientific evidence necessary to receive self-affirmed Generally Recognized as Safe (GRAS) status. CV Sciences, Inc. has primary offices and facilities in San Diego, California.  Additional information is available from OTCMarkets.com or by visiting .

FORWARD-LOOKING DISCLAIMER

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.

About the Hemp Industries Association ®

Hemp Industries Association ® (HIA®) is a 501(c)(6), membership-based, non-profit organization that works to advance the hemp economy and educate the market for the benefit of members, the public, and the planet. Since its founding in 1994, The HIA has worked tirelessly for its 1,500-plus members to expand and protect the sale and marketing of hemp products. The culmination of that work was the passing of the 2018 Farm Bill, which officially redefined hemp as an agricultural commodity and removed it from the purview of the Controlled Substances Act, thereby paving the way for a massive expansion of the market and positioning hemp producers to be a global economic force.

For more information, visit

CONTACT INFORMATION:

Investor Contact:

ICR

Scott Van Winkle

617-956-6736

Media Contact:

ICR

Cory Ziskind

646-277-1232

 

EN
24/10/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CV Sciences Inc

 PRESS RELEASE

CV Sciences, Inc. Reports First Quarter 2022 Financial Results

CV Sciences, Inc. Reports First Quarter 2022 Financial Results SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced its financial results for the quarter ended March 31, 2022. First Quarter 2022 and Recent Financial and Operating Highlights Revenue of $4.4 million for first quarter of 2022, compared to $4.8 million for the first quarter of 2021;Gross margin of 26.0% for first quarter of 2022, compared to 32.4% for t...

 PRESS RELEASE

CV Sciences, Inc. to Announce First Quarter 2022 Results On May 16, 2...

CV Sciences, Inc. to Announce First Quarter 2022 Results On May 16, 2022 SAN DIEGO, May 12, 2022 (GLOBE NEWSWIRE) --  (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced that it will release financial results for the first quarter ended March 31, 2022, before the stock market opens on Monday, May 16, 2022. The Company will hold a conference call with the investment community at 7:00 a.m. Pacific Time (10:00 a.m. Eastern Time) that same day. The webcast of the conference call will be ...

 PRESS RELEASE

CV Sciences, Inc. Reports Fiscal Year-End 2021 Financial Results

CV Sciences, Inc. Reports Fiscal Year-End 2021 Financial Results SAN DIEGO, March 31, 2022 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced its financial results for the year ended December 31, 2021. Fiscal 2021 and Recent Financial and Operating Highlights Revenue of $20.0 million for fiscal year 2021, compared to $24.4 million for 2020;Gross margin of 43.0% for fiscal year 2021, compared to 45.1% for 2020;Total cash balance of $1.4 million a...

 PRESS RELEASE

CV Sciences, Inc. to Announce Fourth Quarter and Full Year 2021 Result...

CV Sciences, Inc. to Announce Fourth Quarter and Full Year 2021 Results on March 31, 2022 SAN DIEGO, March 28, 2022 (GLOBE NEWSWIRE) --  (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced that it will release financial results for the fourth quarter and full year ended December 31, 2021, after the stock market closes on Thursday, March 31, 2022. The Company will hold a conference call with the investment community at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) that same day. The ...

 PRESS RELEASE

UPDATE -- CV Sciences Adds +PlusCBD Relief Softgels to Wellness Line o...

UPDATE -- CV Sciences Adds +PlusCBD Relief Softgels to Wellness Line of CBD Products New softgels deliver seven times more CBDA and CBD than original raw formula to support a healthy inflammatory response and to manage occasional soreness SAN DIEGO, March 11, 2022 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced the addition of +PlusCBD Relief Softgels to its Wellness line of CBD products, joining our highly successful +PlusCBD Sleep & Calm Gu...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch